Dr. Fehrenbacher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
975 Sereno Dr
Vallejo, CA 94589Phone+1 707-651-1000
Education & Training
- University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1976 - 1978
- Kaiser Permanente Northern California (San Francisco)Residency, Internal Medicine, 1973 - 1976
- David Geffen School of Medicine at UCLAClass of 1973
Certifications & Licensure
- CA State Medical License 1974 - 2022
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma Start of enrollment: 2001 Jun 01
- Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2003 Jun 01
- Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Start of enrollment: 2005 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 829 citationsBlood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabDavid R. Gandara, Sarah M. Paul, Marcin Kowanetz, Erica B. Schleifman, Wei Zou
Nature Medicine. 2018-08-06 - 432 citationsPertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled...Sandra M Swain, David Miles, Sung Bae Kim, Young-Hyuck Im, Seock-Ah Im
The Lancet. Oncology. 2020-04-01 - 3930 citationsTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerEdward H. Romond, Edith A. Perez, John Bryant, Vera J. Suman, Charles E. Geyer
The New England Journal of Medicine. 2005-10-20
Press Mentions
- Adjuvant Trastuzumab Did Not Improve Outcomes for Patients with HER2-Low Breast CancerDecember 6th, 2017
- Experimental Targeted Immunotherapy Drug Performs Better Than Chemotherapy for Treatment of Advanced Lung Cancer Kaiser Permanente Clinical Trial Also Shows Genetic Biomarkers Can Help Predict Who Responds Best to TherapyMarch 15th, 2016
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: